Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kinnate Biopharma Inc
(NQ:
KNTE
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Apr 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kinnate Biopharma Inc
< Previous
1
2
3
4
Next >
10 Analysts Have This to Say About Kinnate Biopharma
June 08, 2023
Via
Benzinga
The Latest Analyst Ratings for Kinnate Biopharma
June 08, 2023
Via
Benzinga
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
June 01, 2023
From
Kinnate Biopharma
Via
GlobeNewswire
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029
June 01, 2023
EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END
Via
FinancialNewsMedia
Expert Ratings for Kinnate Biopharma
May 18, 2023
Via
Benzinga
What 4 Analyst Ratings Have To Say About Kinnate Biopharma
April 18, 2023
Via
Benzinga
Kinnate Biopharma in Focus: Analyst's Adjusted Price Target and the Potential of KIN-3248
May 18, 2023
HC Wainwright has lowered the price target for Kinnate Biopharma Inc (NASDAQ: KNTE) to $24 from
Via
Benzinga
Kinnate Biopharma Inc. Reports First Quarter 2023 Financial Results and Recent Corporate Updates
May 11, 2023
From
Kinnate Biopharma
Via
GlobeNewswire
7 Stocks With Promising Upside Potential for 100% Returns
May 07, 2023
If you still want to gamble even during this market environment, these are the stocks with 100% upside potential.
Via
InvestorPlace
Trilogy Metals And 2 Other Penny Stocks Insiders Are Aggressively Buying
May 03, 2023
The Dow Jones closed lower by over 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Kinnate Biopharma Inc. Adds Two New Drug Candidates to Its Growing Targeted Oncology Pipeline and Provides Cash Runway Guidance
April 17, 2023
From
Kinnate Biopharma
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
April 20, 2023
During Thursday's session, 99 companies made new 52-week lows.
Via
Benzinga
First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a Single Agent and in Combination with Binimetinib in BRAF-altered Cancers and NRAS Mutant Melanoma
April 17, 2023
From
Kinnate Biopharma
Via
GlobeNewswire
Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate Updates
March 15, 2023
From
Kinnate Biopharma
Via
GlobeNewswire
Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exarafenib (KIN-2787), in an Oral Presentation at the AACR 2023 Annual Meeting
March 14, 2023
From
Kinnate Biopharma
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
March 06, 2023
On Monday, 36 companies set new 52-week lows.
Via
Benzinga
Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 13, 2023
Gainers Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash.
Via
Benzinga
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca
February 25, 2023
Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between...
Via
Talk Markets
Kinnate Biopharma Inc. Announces Acquisition of Ownership Stake from Series A Investors of the China Joint Venture, Kinnjiu Biopharma Inc., and Initiation of Phase 1 Clinical Trial for Exarafenib (KIN-2787) in People's Republic of China
February 21, 2023
From
Kinnate Biopharma
Via
GlobeNewswire
Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor
February 14, 2023
From
Kinnate Biopharma
Via
GlobeNewswire
Kinnate Biopharma Inc. to Participate in the 2023 SVB Securities Global Biopharma Conference
February 06, 2023
From
Kinnate Biopharma
Via
GlobeNewswire
Kinnate Biopharma Inc. Adds Global Business and Oncology Expertise to Board of Directors with Appointment of Jill DeSimone as Independent Director
January 26, 2023
From
Kinnate Biopharma
Via
GlobeNewswire
Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium
January 17, 2023
From
Kinnate Biopharma
Via
GlobeNewswire
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
November 18, 2022
Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday.
Via
Benzinga
Why Elevate Credit Shares Are Trading Higher By Over 71%? Here Are 43 Stocks Moving In Thursday's Mid-Day Session
November 17, 2022
Gainers Elevate Credit, Inc. (NYSE: ELVT) shares surged 71.2% to $1.8150 after the company agreed to be acquired by Park Cities Asset Management in an all-cash transaction at an implied value of $67...
Via
Benzinga
BrightView Holdings, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday
November 17, 2022
U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Thursday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
November 17, 2022
Upgrades
Via
Benzinga
Walmart To Surge Around 9%? Plus B of A Securities Slashes PT On This Stock By 80%
November 17, 2022
Credit Suisse raised the price target on Walmart Inc. (NYSE: WMT) from $145 to $160. Credit Suisse analyst Robert Moskow maintained an Outperform rating on the stock. Walmart shares fell 0.5% to...
Via
Benzinga
Kinnate Biopharma Inc. Announces Third Quarter 2022 Financial Results and Recent Corporate Updates
November 10, 2022
From
Kinnate Biopharma
Via
GlobeNewswire
Why Norwegian Cruise Line Shares Climbed By Around 12%; Here Are 66 Biggest Movers From Yesterday
October 13, 2022
Gainers Pintec Technology Holdings Limited (NASDAQ: PT) shares jumped 216.2% to close at $0.9058 on Wednesday.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.